Orphazyme: Home run moves nearer (and with funding in place)
The case for Orphazyme continues to strengthen as arimoclomol’s US early access program reinforces a raft of positive data and regulatory progress over the past year. The company is now on the verge of starting to harvest its lead project’s USD1bn-plus sales potential, with launch for NPC likely next year in both Europe and the US.